Phase 3 meets eGFR primary endpoint and suggests best-case scenario
The phase 3 NefIgArd trial with Nefecon (Tarpeyo/Kinpeygo) met the primary endpoint of a two-year benefit on eGFR vs. placebo. We expect to see more details in the call later today, but Calliditas already stated that the benefit was observed irrespective of UPCR (proteinuria) at baseline. We believ
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.